Edward Gomperts
Principal investigator, leads Hillhurst Biopharmaceuticals, Inc..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$13.6MFederal grants as PI28 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
28 awards · $13.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 16, 2025 | NIH | SBIR Phase II HBI-002 to Treat Diabetic Retinopathy | $961K | Hillhurst Biopharmaceuticals, Inc. |
| Jul 29, 2025 | NIH | SBIR Phase II HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | $1000K | Hillhurst Biopharmaceuticals, Inc. |
| Sep 12, 2024 | NIH | SBIR Phase II HBI-002 to Treat Diabetic Retinopathy | $950K | Hillhurst Biopharmaceuticals, Inc. |
| Apr 10, 2024 | NIH | SBIR Phase II HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | $1000K | Hillhurst Biopharmaceuticals, Inc. |
| Apr 10, 2024 | NIH | STTR Phase I HBI-002 for Cystic Fibrosis | $300K | Hillhurst Biopharmaceuticals, Inc. |
| Jul 25, 2023 | NIH | STTR Phase I Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury | $300K | Hillhurst Biopharmaceuticals, Inc. |
| Mar 13, 2023 | NIH | SBIR Phase II HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | $1000K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 22, 2022 | NIH | STTR Phase I HBI-002 to Treat Parkinson’s Disease | $181K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 11, 2022 | NIH | STTR Phase I Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury | $300K | Hillhurst Biopharmaceuticals, Inc. |
| Sep 17, 2021 | NIH | STTR Phase I HBI-002 to Treat Parkinson’s Disease | $453K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 18, 2021 | NIH | STTR Phase I HBI-002 to Treat Diabetic Retinopathy | $300K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 10, 2021 | NIH | STTR Phase I HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | $17K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 4, 2021 | NIH | STTR Phase I HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | $77K | Hillhurst Biopharmaceuticals, Inc. |
| Apr 28, 2021 | NIH | STTR Phase I HBI-002 to Treat Ulcerative Colitis | $75K | Hillhurst Biopharmaceuticals, Inc. |
| Apr 27, 2021 | NIH | STTR Phase I Laboratory training and experience for an undergraduate | $6K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 9, 2020 | NIH | STTR Phase I HBI-002 to Prevent Anthracycline-Related Cardiotoxicity | $222K | Hillhurst Biopharmaceuticals, Inc. |
| May 15, 2020 | NIH | STTR Phase I HBI-002 to Treat Ulcerative Colitis | $219K | Hillhurst Biopharmaceuticals, Inc. |
| Jul 23, 2019 | NIH | SBIR Phase II HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | $702K | Hillhurst Biopharmaceuticals, Inc. |
| Mar 12, 2019 | NIH | SBIR Phase I HBI-002 to Treat Traumatic Injury | $56K | Hillhurst Biopharmaceuticals, Inc. |
| Sep 20, 2018 | NIH | SBIR Phase II HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | $1.3M | Hillhurst Biopharmaceuticals, Inc. |
| Apr 1, 2018 | NIH | SBIR Phase I HBI-002 to Treat Traumatic Injury | $225K | Hillhurst Biopharmaceuticals, Inc. |
| Jul 17, 2017 | NIH | SBIR Phase II HBI-002 to Treat Delayed Graft Function in Kidney Transplant | $635K | Hillhurst Biopharmaceuticals, Inc. |
| Mar 22, 2017 | NIH | SBIR Phase I Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | $42K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 19, 2016 | NIH | SBIR Phase I Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke | $224K | Hillhurst Biopharmaceuticals, Inc. |
| Aug 15, 2016 | NIH | SBIR Phase II HBI to Treat Delayed Graft Function in Kidney Transplant | $1.5M | Hillhurst Biopharmaceuticals, Inc. |
| Aug 11, 2016 | NIH | SBIR Phase II HBI-002 to Treat Delayed Graft Function in Kidney Transplant | $863K | Hillhurst Biopharmaceuticals, Inc. |
| Apr 7, 2016 | NIH | SBIR Phase I Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | $258K | Hillhurst Biopharmaceuticals, Inc. |
| Sep 4, 2015 | NIH | SBIR Phase I Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke | $476K | Hillhurst Biopharmaceuticals, Inc. |
Peer ranks
Federal funding#28
Awards as PI#8
Patents#273
Companies
- Hillhurst Biopharmaceuticals, Inc.Leads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.